{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:24:09Z","timestamp":1772310249082,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10637-017-0531-3","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T03:24:14Z","timestamp":1509593054000},"page":"619-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors"],"prefix":"10.1007","volume":"36","author":[{"given":"Rastislav","family":"Bahleda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apexa","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Poterie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"Van De Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Sallansonnet-Froment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Taillia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Angevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"issue":"6","key":"531_CR1","first-page":"2297","volume":"31","author":"T Fukushima","year":"2011","unstructured":"Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T et al (2011) Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 31(6):2297\u20132302","journal-title":"Anticancer Res"},{"issue":"11","key":"531_CR2","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108\u20132121","journal-title":"J Clin Oncol"},{"issue":"5","key":"531_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440","journal-title":"Lancet Oncol"},{"issue":"3","key":"531_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP (2011) Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 11(3):239\u2013253","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"531_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ (2000) Proteasome inhibition measurements: Clinical Application. Clin Chem 46(5):673\u2013683","journal-title":"Clin Chem"},{"issue":"5","key":"531_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","volume":"86","author":"M Delforge","year":"2011","unstructured":"Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R et al (2011) Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan prednisone versus melphalan-prednisone in the phase III VISTAtrial in multiple myeloma. Eur J Haem 86(5):372\u2013384","journal-title":"Eur J Haem"},{"issue":"3","key":"531_CR7","first-page":"657","volume":"27","author":"X Trinh","year":"2012","unstructured":"Trinh X, Sas L, Van Laere SJ, Prov\u00e9 A, Deleu I, Rasschaert M et al (2012) A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine resistant metastatic breast cancer. Oncol Rep 27(3):657\u2013663","journal-title":"Oncol Rep"},{"key":"531_CR8","doi-asserted-by":"crossref","unstructured":"Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93(12):1908-1911","DOI":"10.3324\/haematol.13285"},{"issue":"8","key":"531_CR9","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8(8):2505\u20132511","journal-title":"Clin Cancer Res"},{"issue":"4","key":"531_CR10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1002\/phar.1383","volume":"34","author":"CM Zobniw","year":"2014","unstructured":"Zobniw CM, Saad S, Kostoff D, Barthel BG (2014) Bortezomib-Induced Sweet's Syndrome Confirmed by Rechallenge. Pharmacotherapy 34(4):e18\u2013e21","journal-title":"Pharmacotherapy"},{"issue":"3","key":"531_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4103\/0378-6323.152743","volume":"81","author":"M Llamas-Velasco","year":"2015","unstructured":"Llamas-Velasco M, Concha-Garz\u00f3n MJ, Fraga J, Arag\u00fc\u00e9s M (2015) Histiocytoid sweet syndrome related to bortezomib: A mimicker of cutaneous infiltration by myeloma. Indian J Dermatol Venereol Leprol 81(3):305\u2013306","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"12","key":"531_CR12","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/j.1365-4632.2011.05141.x","volume":"51","author":"JS Kim","year":"2012","unstructured":"Kim JS, Roh HS, Lee JW, Lee MW, Yu HJ (2012) Distinct variant of Sweet\u2019s syndrome: bortezomib-induced histiocytoid Sweet\u2019s syndrome in a patient with multiple myeloma. Int J Dermatol 51(12):1491\u20131493","journal-title":"Int J Dermatol"},{"issue":"1","key":"531_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.18632\/oncotarget.103","volume":"1","author":"S Duensing","year":"2010","unstructured":"Duensing S, Duensing A (2010) Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget 1(1):6\u20138","journal-title":"Oncotarget"},{"issue":"6","key":"531_CR14","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/0008-5472.CAN-06-3497","volume":"67","author":"Y Liu","year":"2007","unstructured":"Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P et al (2007) Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 67(6):2685\u20132692","journal-title":"Cancer Res"},{"issue":"1","key":"531_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/0008-5472.CAN-09-1449","volume":"70","author":"S Bauer","year":"2010","unstructured":"Bauer S, Parry JA, Muhlenberg T, Brown MF, Seneviratne D, Chatterjee P et al (2010) Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res 70(1):150\u2013159","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0531-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:21:55Z","timestamp":1678558915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0531-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0531-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]},"assertion":[{"value":"6 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HVDV: Employment Millennium Pharmaceuticals, Cambridge, MA; stock ownership Johnson&Johnson.AB: Employment Johnson & Johnson, Raritan, NJ; stock ownership Johnson&Johnson.MH: Employment Millennium Pharmaceuticals Inc., Cambridge, MA, USA.The other authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}